This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Botulinum neurotoxin 3D structures
From Proteopedia
(Difference between revisions)
| (One intermediate revision not shown.) | |||
| Line 12: | Line 12: | ||
*Type A Light Chain residues 1-425 | *Type A Light Chain residues 1-425 | ||
| - | **[[2g7k]], [[2g7p]], [[2g7q]], [[2imc]], [[3bwi]], [[3bon]], [[3qix]], [[2ise]], [[2isg]], [[2ish]], [[4ej5]] - CbCBN LC + Zn<br /> | + | **[[2g7k]], [[2g7p]], [[2g7q]], [[2imc]], [[3bwi]], [[3bon]], [[3qix]], [[2ise]], [[2isg]], [[2ish]], [[4ej5]], [[7ky2]], [[7kyf]], [[7kyh]] - CbCBN LC + Zn<br /> |
**[[5vgv]] - CbCBN LC + Cu<br /> | **[[5vgv]] - CbCBN LC + Cu<br /> | ||
**[[5vgx]] - CbCBN LC + Hg<br /> | **[[5vgx]] - CbCBN LC + Hg<br /> | ||
| Line 21: | Line 21: | ||
**[[3dda]], [[3ddb]] - CbCBN LC + synaptosomal-associated protein 25 peptide + Zn<br /> | **[[3dda]], [[3ddb]] - CbCBN LC + synaptosomal-associated protein 25 peptide + Zn<br /> | ||
**[[3zur]], [[3zus]] - CbCBN LC/synaptosomal-associated protein 25 translocation domain<br /> | **[[3zur]], [[3zus]] - CbCBN LC/synaptosomal-associated protein 25 translocation domain<br /> | ||
| - | **[[2g7n]], [[2ilp]], [[2imb]], [[3qiy]], [[3qiz]], [[3qj0]], [[4hev]], [[2ima]], [[5v8r]] – CbCBN LC + inhibitor + Zn<br /> | + | **[[2g7n]], [[2ilp]], [[2imb]], [[3qiy]], [[3qiz]], [[3qj0]], [[4hev]], [[2ima]], [[5v8r]], [[6xcb]], [[6xcc]], [[6xce]], [[6xcf]], [[7n18]] – CbCBN LC + inhibitor + Zn<br /> |
**[[3c88]], [[3c89]], [[3c8a]], [[3c8b]], [[3boo]], [[3qw5]], [[3qw6]], [[3qw7]], [[3qw8]], [[3nf3]] – CbCBN LC + inhibitor peptide + Zn<br /> | **[[3c88]], [[3c89]], [[3c8a]], [[3c8b]], [[3boo]], [[3qw5]], [[3qw6]], [[3qw7]], [[3qw8]], [[3nf3]] – CbCBN LC + inhibitor peptide + Zn<br /> | ||
**[[4ks6]], [[4ktx]], [[5v8p]], [[5v8u]] - CbCBN LC (mutant) + inhibitor peptide + Zn<br /> | **[[4ks6]], [[4ktx]], [[5v8p]], [[5v8u]] - CbCBN LC (mutant) + inhibitor peptide + Zn<br /> | ||
**[[3ds9]] – CbCBN LC (mutant) + inhibitor peptide + Zn + Ni<br /> | **[[3ds9]] – CbCBN LC (mutant) + inhibitor peptide + Zn + Ni<br /> | ||
**[[3k3q]] - CbCBN LC + antibody + Zn<br /> | **[[3k3q]] - CbCBN LC + antibody + Zn<br /> | ||
| + | **[[7l6v]], [[7lzp]], [[7m1h]] - CbCBN LC + nanobody + Zn<br /> | ||
*Type A translocation domain residues 547-871 | *Type A translocation domain residues 547-871 | ||
| Line 32: | Line 33: | ||
**[[6mhj]] - CbCBN (mutant) <br /> | **[[6mhj]] - CbCBN (mutant) <br /> | ||
| - | *Type A receptor-binding domain residues 871-1296 | + | *Type A receptor-binding or heavy chain domain residues 871-1296 |
| - | **[[2vua]], [[3fuo]], [[5tpb]], [[5tpc]], [[5lr0]], [[5mk6]], [[5mk7]] – CbPBN <br /> | + | **[[2vua]], [[3fuo]], [[5tpb]], [[5tpc]], [[5lr0]], [[5mk6]], [[5mk7]], [[6f0o]], [[6f0p]], [[6twp]], [[6two]], [7dvl]], [[7z5t]], [[8alp]] – CbPBN <br /> |
**[[4iqp]] – CbPBN (mutant)<br /> | **[[4iqp]] – CbPBN (mutant)<br /> | ||
| + | **[[7qpt]], [[7qpu]], [[7z5s]], [[8agk]] – CbPBN + oligosaccharide <br /> | ||
**[[2vu9]] – CbPBN + polysaccharide + Mg<br /> | **[[2vu9]] – CbPBN + polysaccharide + Mg<br /> | ||
**[[4jra]], [[5jlv]], [[5moy]], [[6es1]] – CbCBN + synaptic vesicle glycoprotein 2C<br /> | **[[4jra]], [[5jlv]], [[5moy]], [[6es1]] – CbCBN + synaptic vesicle glycoprotein 2C<br /> | ||
| Line 47: | Line 49: | ||
**[[6ui1]], [[6ul6]] – CbCBN + VHH<br /> | **[[6ui1]], [[6ul6]] – CbCBN + VHH<br /> | ||
| - | *'''Type B''' | + | *'''Type B residues 1-1291''' |
| + | **[[7qfq]] – CbCBN (mutant) – Cryo EM<br /> | ||
**[[1s0b]], [[1s0c]], [[1s0d]], [[1s0e]], [[1s0f]], [[1s0g]], [[1epw]] – CbCBN + Zn<br /> | **[[1s0b]], [[1s0c]], [[1s0d]], [[1s0e]], [[1s0f]], [[1s0g]], [[1epw]] – CbCBN + Zn<br /> | ||
**[[6g5f]] – CbCBN + synaptotagmin-1<br /> | **[[6g5f]] – CbCBN + synaptotagmin-1<br /> | ||
| Line 60: | Line 63: | ||
**[[2etf]], [[1f82]] - CbCBN LC + Zn<br /> | **[[2etf]], [[1f82]] - CbCBN LC + Zn<br /> | ||
| + | **[[7na9]], [[7t5f]] - CbCBN LC + Zn + nanobody<br /> | ||
*Type B Light+Heavy Chain translocation domain residues 1-858 | *Type B Light+Heavy Chain translocation domain residues 1-858 | ||
| Line 67: | Line 71: | ||
*Type B receptor-binding domain residues 857-1291 | *Type B receptor-binding domain residues 857-1291 | ||
| - | **[[1z0h]] – CbCBN <br /> | + | **[[1z0h]], [[6zvm]] – CbCBN <br /> |
| - | **[[6g5k]] - CbCBN + synaptotagmin-1 peptide<br /> | + | **[[6g5k]], [[6zvn]] - CbCBN + synaptotagmin-1 peptide<br /> |
**[[6qns]] - CbCBN (mutant) + synaptotagmin-1 peptide<br /> | **[[6qns]] - CbCBN (mutant) + synaptotagmin-1 peptide<br /> | ||
**[[2nm1]], [[4kbb]] - CbCBN + synaptotagmin-2 peptide<br /> | **[[2nm1]], [[4kbb]] - CbCBN + synaptotagmin-2 peptide<br /> | ||
| Line 105: | Line 109: | ||
*Type E | *Type E | ||
| + | **[[7qfp]] – CbCBN – Cryo EM<br /> | ||
**[[3ffz]], [[4zkt]] – CbCBN + Zn<br /> | **[[3ffz]], [[4zkt]] – CbCBN + Zn<br /> | ||
| + | **[[7k7y]], [[7k84]] - CbCBN + VHH<br /> | ||
| + | **[[7ovw]] – CbPBN + oligosaccharide <br /> | ||
*Type E Light Chain | *Type E Light Chain | ||
| Line 128: | Line 135: | ||
**[[2vxr]], [[3mpp]] - CbCBN <br /> | **[[2vxr]], [[3mpp]] - CbCBN <br /> | ||
| + | |||
| + | *Type H Light Chain | ||
| + | |||
| + | **[[6bvd]] - CbCBN LC + Zn<br /> | ||
*Type X Light Chain | *Type X Light Chain | ||
| Line 133: | Line 144: | ||
**[[6f4e]] - CbCBN LC<br /> | **[[6f4e]] - CbCBN LC<br /> | ||
**[[6f47]], [[6g8u]], [[6g8v]] - CbCBN LC + Zn<br /> | **[[6f47]], [[6g8u]], [[6g8v]] - CbCBN LC + Zn<br /> | ||
| + | **[[7kz7]] - CbCBN LC (mutant) + Zn<br /> | ||
}} | }} | ||
[[Category: Topic Page]] | [[Category: Topic Page]] | ||
Current revision
3D structures of botulinum neurotoxin
Updated on 03-November-2022
